Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P210011/S002

xT CDx

Tempus AI, Inc. · Decision date Sep 2, 2026

MEDTECHLEDGER EXPLANATIONP210011/S002

What did the FDA approve?

Supplement S002 to PMA P210011 covers a pre-specified change control plan (PCCP) that would modify use of the device from a single laboratory to multiple laboratories. The listed supplement reason is change in design, components, specifications or material, on the normal 180-day track. The device category is a next generation sequencing oncology panel, somatic or germline variant detection system, in pathology under product code PQP, filed by Tempus AI, Inc.

The source field states approval of the PCCP for that scope change, but does not identify the components or specifications altered, the number or identity of additional laboratories, or supporting data. The statement's purpose is not independent evidence of analytical or clinical performance, and it does not extend the original PMA to new indications.

FDA approval order statement

Approval for a Pre-specified Change Control Plan (PCCP) to modify the use of the device at a single laboratory to multiple laboratories
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Pathology
Decision date
Sep 2, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P210011/S002
Regulatory pathway
PMA supplement
Product code
PQP
Decision code
APPR
Decision date
Sep 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.

Product code
PQP
FDA device class
3

For the original device and its historical approval scope, see PMA P210011. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P210011/S002 received

    Application receipt date recorded by FDA.

  2. P210011/S002 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P210011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210011

Product / regulatory recordCompanyPathwayDecision dateSource
xT CDxP210011
Tempus AI, Inc.PMA approvalApr 28, 2023FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code PQP

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Tempus AI, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
600 W Chicago Ave., Suite #510, Chicago, IL, 60654

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records